Format

Send to

Choose Destination
See comment in PubMed Commons below
Obesity (Silver Spring). 2016 Jul;24(7):1454-63. doi: 10.1002/oby.21523. Epub 2016 May 25.

Efficacy of an orlistat-resveratrol combination for weight loss in subjects with obesity: A randomized controlled trial.

Author information

1
Instituto Biosen A.C, Mexico D.F., Mexico.
2
Departamento de Nutricion, Centro de Diseño y Planeación en Investigación Médica S.C, Guadalajara, Jalisco, Mexico.
3
Departmento de Fisiología de la Nutrición, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico D.F., Mexico.

Abstract

OBJECTIVE:

To evaluate the efficacy of an orlistat-resveratrol (O-R) combination in subjects with obesity over a 6-month period.

METHODS:

This study was a double-blind, parallel, randomized controlled clinical trial. Patients fulfilling the selection criteria (age from 20 to 60 years and body mass index (BMI) ≥30 and ≤39.9 kg/m(2) ) consumed an energy-reduced diet with 500 fewer calories than their usual diet for 2 weeks. Then the participants were randomly assigned to four groups, placebo, resveratrol, orlistat, or O-R, and they consumed the energy-reduced diet for 6 months. The study consisted of seven visits. During each visit, a 24-h recall was performed, along with measurements of anthropometric and serum biochemical parameters.

RESULTS:

A total of 161 participants were selected. Of these, 84 participants completed the study. A significant weight loss of -6.82 kg (95% CI -8.37 to -5.26) was observed in the O-R group compared with -3.50 kg (-5.05 to -1.95, P = 0.021) in the placebo group. In contrast, the -6.02 kg (-7.68 to -4.36) orlistat and -4.68 kg (-6.64 to -2.71) resveratrol monotherapy losses did not significantly differ from the placebo. Significant decreases in BMI, waist circumference, fat mass, triglycerides, leptin, and leptin/adiponectin ratio were observed with the O-R combination.

CONCLUSIONS:

The O-R combination was the most effective weight loss treatment.

PMID:
27221771
DOI:
10.1002/oby.21523
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center